Abstract
PATIENTS WITH acute venous thrombosis or pulmonary embolism (PE) (venous thromboembolism [VTE]) are at high risk of recurrence unless they are treated with an adequate course of anticoagulants.<sup>1,2</sup>Anticoagulant therapy is very effective for the treatment of VTE but is associated with bleeding.<sup>3</sup>The risk of recurrence is highest early after the acute episode and then declines over time. Ideally, treatment should be continued until the benefits of treatment are offset by the risks, but this optimal duration is uncertain because both the risk of recurrence after discontinuing treatment and the risk of bleeding during anticoagulation therapy are not easily predicted in individual patients. For most patients, the benefits of 3 to 6 months of anticoagulant therapy greatly outweigh the risks.<sup>1,4</sup>In addition, some patients, for example those with familial thrombophilia, remain at high risk for recurrence even after completing such a course of anticoagulants<sup>5,6</sup>; consequently,
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
